Ingenol-3-angelate
PKC activator / Selective activator of protein kinase C which displays antileukemic activity mediated via PKC1 In contrast, it provides a strong survival signal to resting and activated human T cells via activation of PKC and downstream activation of NFB.2 Treatment of subcutaneous tumors results in anti-cancer CD8 T cells, also displays adjuvant activity and synergizes with cancer immunotherapies.3 Induces senescence-like growth arrest in solid tumor cells.4 Inhibits HIV-1 infection at an early pathway of viral entry.5
Biochemicals & reagents
75567-37-2
PEP-005
1) Hampson et al. (2005), PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC; Blood, 106 1362 2) Lee et al. (2010), Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta; J. Biol. Chem., 285 23889 3) Le et al. (2009), Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies; Vaccine, 27 3053 4) Mason et al. (2010), The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells; Invest. New Drugs, 28 575 5) Warrilow et al. (2006), HIV type 1 inhibition by protein kinase C modulatory compounds; AIDS Res. Hum. Retroviruses, 22 854
-20°C
TARGET: Kinase -- PATHWAY: NFkappaB; Senescence; Apoptosis inducer; Cytokine -- RESEARCH AREA: Immunology; Cell death -- DISEASE AREA: Cancer; Infectious diseaseInflammation; Ageing